Results 201 to 210 of about 2,071,364 (242)

Anti-IgE therapy for asthma: an audit at atertiary care centre in Saudi Arabia. [PDF]

Ann Saudi Med, 2018
Weheba IM, Abdelsayed AM, Arnaout RK, Zeitouni MO, Mobaireek KF, AlHarthi TB, Mobeireek AF.   +6 more
europepmc   +1 more source

Protein Corona‐Coated Crystal Silica From Sandstorms Amplifies Allergic Rhinitis by Regulating Epithelial Integrity in Mice and Human Nasal Epithelia

Allergy, EarlyView.
Cuishuang Dong, Xu Zhang, Haoyue Wang, Jiajing Cui, Shuai Han, Yibo Wang, Huanying Zhao, Yang Song, Yuan Zhang, Xiaobo Li   +9 more
wiley   +1 more source

Influence of Environmental Pollution on Basophil Reactivity to Birch Pollen Allergens in Atopic and Non‐Atopic Subjects

Allergy, EarlyView.
Birch pollen and PM10 are key determinants of clinical symptoms, particularly in asthma. Allergic people react stronger to the pollen collected in the highly polluted area than in the less polluted areas. When evaluating the effectiveness of allergen immunotherapy, it is essential to consider not only pollen concentrations but also levels of air ...
Maria Czarnobilska, Małgorzata Bulanda, Ewa Czarnobilska, Wojciech Dyga, Marek Jutel, Dorota Myszkowska   +5 more
wiley   +1 more source

Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. [PDF]

Cochrane Database Syst Rev, 2018
Jat KR, Walia DK, Khairwa A.
europepmc   +1 more source

m6A‐Related Regulation of Ferroptosis Contributes to Nasal Epithelial Barrier Dysfunction in Allergic Rhinitis

Allergy, EarlyView.
This study uses human nasal epithelial cells and BALB/c mice to evaluate the role and molecular mechanism of ferroptosis in HDM‐induced AR, focusing on ferroptosis‐related responses and nasal epithelial barrier disruption. HDM exposure induces lipid peroxidation‐driven ferroptosis and epithelial barrier disruption.
Zehua Lin, Baoai Han, Qiang Xie, Aikebaier Tuohuti, Weisong Cai, Peng Zhou, Jiahao Meng, Qiuyang Fu, Zuhong He, Xiong Chen   +9 more
wiley   +1 more source

Nomenclature on Immune‐Mediated Drug Reactions: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT Over the past several decades, there have been significant advances in our understanding of both immunological and pharmacological mechanisms of adverse drug reactions (ADRs). Immune‐mediated drug reactions (IMDRs) represent a small proportion of ADRs and are caused by a pathological activation of the immune system or inflammatory pathways ...
Maria J. Torres, Cristobalina Mayorga, Elizabeth J. Phillips, Adriana Ariza, Annick Barbaud, Patrizia Bonadonna, Mariana Castells, Gülfem Çelik, Knut Brockow, Lene H. Garvey, Inmaculada Doña, Jean‐Christoph Caubet, Francesca Mori, Jason Trubiano, Giorgia Marta, Antonino Romano, Ingrid Terreehorst, Asli Gelincik, Philip H. Li, Vito Sabato   +19 more
wiley   +1 more source

Eosinophilia Reflects Type 2 Immune Activation in Newly Diagnosed Bullous Pemphigoid, With No Evidence of Charcot‐Leyden Crystals

Allergy, EarlyView.
Janik Fleißner, Tassilo Dege, Sandrine Benoit, Matthias Goebeler, Andreas Kerstan   +4 more
wiley   +1 more source

Human IgE Antibodies Recognize the Vicilin and Alpha‐Hairpinin Domains of Peanut Allergen Ara h 1

Allergy, EarlyView.
The ɑ‐hairpinin of Ara h 1 contains a dominant epitope that is both frequently recognized and blocks a majority of the IgE against this domain. Including this region in tests may improve diagnosis of peanut allergy. The trimeric structure of the vicilin region explains the ability of Ara h 1 to induce anaphylaxis with a single antibody.
Taylor M. Cosey, Gage O. Leighton, Emmanuel R. De Diavoukana, Min Shi, Alexander C. Y. Foo, Anna Pomés, Jacqueline B. Nesbit, Stephen A. Y. Gipson, Paige Creeks, Jian Zhang, R. Stokes Peebles, Soheila J. Maleki, Derek Croote, Scott A. Smith, Geoffrey A. Mueller   +14 more
wiley   +1 more source

Pre‐Seasonal Treatment With Recombinant Carrier‐Based Birch Vaccine Improves Birch Pollen Allergy

Allergy, EarlyView.
We conducted a two stage SCIT trial with GNR‐127 containing a recombinant fusion protein consisting of Bet v 1 and Mal d 1‐derived peptides fused to PreS from HBV. Stage 1 identified two safe maximum tolerated doses (40 μg and 80 μg). In the following Stage 2, five preseasonal injections were well tolerated, induced dose‐dependent allergen‐specific IgG,
Musa R. Khaitov, Maria G. Byazrova, Evgenii V. Smolnikov, Vladislav N. Turenko, Valeriy V. Smirnov, Igor P. Shilovskii, Nadezhda N. Shershakova, Ekaterina N. Medunitsyna, Olga G. Elisyutina, Mikhail V. Pashenkov, George B. Pasikhov, Vladimir V. Murugin, Veronika A. Parshina, Darya K. Bolyakina, Anastasia S. Primak, Mariya A. Lapyko, Inna V. Danilycheva, Rosalia V. Schubelko, Anastasia A. Tsyvkina, Nataliia V. Shartanova, Daria O. Timoshenko, Irina I. Isakova, Tatiana V. Latysheva, Andrey E. Shulzhenko, Elena A. Latysheva, Oksana M. Kurbacheva, Elena S. Fedenko, Oksana A. Markova, Ilya A. Korotkevich, Violetta V. Yan, Natalia A. Gavrilova, Mariia V. Tikhomirova, Ivan V. Shevchenko, Alena A. Agafonova, Gregory N. Poroshin, Dmitry A. Kudlay, Alexander V. Filatov, Evgeniya V. Nazarova, Daria S. Kruchko, Dmitriy V. Goryachev, Vadim A. Merkulov, Nataliya I. Ilina, Rudolf Valenta, Veronica I. Skvortsova   +43 more
wiley   +1 more source